[Treatment of bone metastases with bisphosphonates].
Bone metastasis are very common in many cancers; metastatic bone disease is the most common cause of cancer pain and also of serious complications, which reduce the quality of life of these patients. Management of skeletal cancer involves a multimodality approach who include bisphosphonates, which in association with anti-tumour treatments reduce the apparition of new skeletal-related events (SRE) and prolong the delay to first SRE. They although reduce the pain of bone metastasis. All this facts do the quality of life better.
Gremaud
M
M
Service cantonal multisite d'oncologie et de radio-oncologie, Hôpital de la Chaux-de-Fonds, Case postale, 2303 La Chaux-de-Fonds. magali.gremaud@ne.ch
Delouche
D
D
Monnerat
C
C
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans
D050071:Bone Density Conservation Agents; D004164:Diphosphonates